Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

Ultimately, the return from Vancouver doesn’t matter all that much. The most important part about this trade for the Oilers is that they didn’t have to retain any of the $5.125 million owed to ...

3 Galafold (migalastat) estimated mean annualized eGFR slope: -0.4 mL/min/1.73m2/year (95% CI: -2.27, 1.48) (Source: Hughes, 2016: Oral pharmacological chaperone migalastat compared with enzyme ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a clinical-stage biotechnology company with a market capitalization of $103 million and trailing twelve-month revenue of $64 million, ...

Sangamo Therapeutics (NASDAQ: SGMO), a $108.63 million market cap biotech company trading at $0.46 per share, announced positive topline results Tuesday from its registrational Phase 1/2 STAAR study ...

Following a single dose of isaralgagene civoparvovec, a positive mean annualized eGFR (estimated Glomerular Filtration Rate) slope of 1.965 mL/min/1.73m2/year at 52-weeks was observed across all ...